Second positive phase 1 trial data for XF-73

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.  Destiny Pharma plc (“Destiny Pharma” or “the Company”)  Second positive […]

Destiny Pharma awarded significant new grant funding up to £1.6 million under new UK-China AMR programme

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma […]

Destiny Pharma notes UK 5-year action plan on AMR

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma notes release of UK Government’s Vision and 5-year action plan to help tackle anti-microbial resistance (AMR), which includes additional investment in innovation Government’s plan consistent with Destiny Pharma’s objective of developing novel anti-infectives from its proprietary XF platform. Brighton, United Kingdom – 24 January 2019 – Destiny Pharma (AIM: […]

Destiny Pharma announces research collaboration with the University of Southampton targeting infections in diabetic foot ulcers and cystic fibrosis

Brighton, United Kingdom – 1 November 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, that addresses the global problem of antimicrobial resistance (AMR), today announces it has been jointly awarded a National Biofilms Innovation Centre (NBIC) funded research collaboration with the University of Southampton. The […]

Directorate Change

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.  Destiny Pharma plc (“Destiny Pharma” or “the Company”) Directorate Change […]

UK government highlights global threat of AMR

Destiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma’s lead asset, XF-73, well positioned to address the global threat of anti-microbial resistance highlighted in new UK government report Brighton, United Kingdom – 24 October 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address […]

BIA celebrates UK bioscience in creating innovative new drugs and treatment for patients

Destiny Pharma plc (“Destiny Pharma” or the “Company”) A series of videos and explainer documents launched, focusing on cutting-edge R&D taking place in UK biotech companies, including Destiny Pharma Destiny Pharma has been chosen to exemplify the UK’s leading status in antimicrobial resistance research Brighton, United Kingdom – 19 October 2018 – Destiny Pharma (AIM: DEST), […]

Interim results for the six months ended 30 June 2018

Destiny Pharma plc (“Destiny Pharma” or the “Company”)   Interim results for the six months ended 30 June 2018   Clinical progress and pipeline expansion in dermal infections; well-funded through to H2 2020   Brighton, United Kingdom – 26 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development […]

Destiny Pharma announces appointment of Chief Medical Officer

Destiny Pharma plc (“Destiny” or “the Company”) Dr Jesús González brings extensive experience in the clinical development of anti-infectives, as the Company prepares to initiate a Phase 2b trial for lead asset Brighton, United Kingdom – 26 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial […]

Directorate Change New Chairman Appointment

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Brighton, United Kingdom – 6 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), announces that Sir Nigel Rudd is stepping down as Chairman and a member of […]